2021-06-28-世界卫生组织-Virtual_Extraordinary_Meeting_of_Strategic_Advisory_Group_of_Experts_SAGE_on_Immunization_-_Declaration_of_interests_9页_310kb

Summary of SAGE Members' Declaration of Interests (June 29, 2021)

Core Content

This document provides a summary of the Declaration of Interests for all 15 SAGE members who participated in the Virtual Extraordinary Meeting of the Strategic Advisory Group of Experts on Immunization (SAGE) on June 29, 2021. The purpose of this declaration is to disclose any potential conflicts of interest that may arise from their professional and institutional affiliations. It is noted that no product-specific discussions were held during this session, and therefore, all members were assessed as being able to fully participate.

Main Points

• All 15 SAGE members updated their declarations of interest before the meeting.
• No product-specific discussions were conducted, so the risk of conflict was considered low.
• Conflicts of interest were assessed based on three criteria: personal or non-personal, specific or non-specific, and financially significant or insignificant.
• Most interests were categorized as non-personal, non-specific, and financially insignificant, indicating minimal potential for bias.
• A few interests were marked as specific or financially significant, but they were still deemed acceptable for participation in the meeting.

Key Information

Rakesh Aggarwal

• Non-personal, non-specific, financially insignificant interests:
  • Advisory role for NITAG of India
  • Board membership for Australian National Center for Immunization Research and Surveillance
  • International Vaccine Institute (IVI)
• Non-personal, non-specific, financially significant interests:
  • Clinical trials for Ebola vaccines (Ad26.ZEBOV and MVA-BN-Filo) and HIV vaccines (VRC01, ALVAC-HIV, Bivalent Subtype C gp120)
  • Studies on OPV and fIPV immunogenicity
  • Research on vaccine hesitancy and public health recommendations

Shabir Madhi

• Non-personal, non-specific, financially insignificant interests:
  • Advisory role for IVI and previous role on Pfizer GBS vaccine program
  • DSMB roles for GSK and Janssen
• Non-personal, non-specific, financially significant interests:
  • Grants from BMGF, Novartis, GSK, VPM, Medimmune, Novovax, Mitsubishi, MSD for various vaccine studies
• Non-personal, specific, financially significant interests:
  • Involvement in NIH’s COV-VAC Network and trials of multiple manufacturers’ vaccines

Peter McIntyre

• Non-personal, non-specific, financially significant interests:
  • Multiple NIH and NHMRC funded studies on pneumococcal, pertussis, and influenza vaccines
  • Research on vaccine effectiveness and timeliness in Aboriginal and non-Aboriginal infants
• Non-personal, specific, financially significant interests:
  • Participation in NIH’s COV-VAC Network

Kim Mulholland

• Non-personal, non-specific, financially significant interests:
  • Research support from GSK, Pfizer, and the Gates Foundation for various vaccine studies
• Non-personal, specific, financially significant interests:
  • Involvement in NIH’s COV-VAC Network and trials of multiple manufacturers’ vaccines

Kathy Neuzil

• Non-personal, non-specific, financially significant interests:
  • Research support from multiple vaccine manufacturers for pneumococcal and influenza vaccines
• Non-personal, specific, financially significant interests:
  • Involvement in NIH’s COV-VAC Network

Hanna Nohynek

• Non-personal, non-specific, financially significant interests:
  • Research grants from vaccine manufacturers for pediatric pneumococcal and influenza vaccines
• Non-personal, specific, financially insignificant interests:
  • Secretary of THL NITAG and advisory role to Finnish MoH on vaccines

Folake Olayinka

• Non-personal, non-specific, financially insignificant interests:
  • Advisory roles for WHO-AFRO and African Local Initiative for Vaccinology Expertise
  • Chair of IA2030 Content Working Group

Punnee Pitisuttithum

• Non-personal, non-specific, financially significant interests:
  • Principal investigator for multiple vaccine studies, including DTaP and 9vHPV
• Non-personal, non-specific, financially insignificant interests:
  • Chair of UK Department of Health’s Joint Committee on Vaccines and Immunization

Conclusion

The summary indicates that while some SAGE members have financially significant interests in vaccine-related research, these were assessed as non-personal and non-specific, meaning they do not directly influence their participation in the meeting. No product-specific discussions were held, and the overall assessment concluded that all members could fully participate without conflict.